VIDEO: Intervention could reduce economic burden, uncontrolled gout in US adults with CKD
Click Here to Manage Email Alerts
Key takeaways:
- The prevalence of comorbid gout and chronic kidney disease could reach 10.5 million adults in 2035.
- Pegloticase use could result in 301,000 fewer uncontrolled gout cases in the study cohort by 2035.
PHILADELPHIA — Gout prevalence in U.S. adults with chronic kidney disease is expected to markedly increase during the next 12 years, suggests data presented at ASN Kidney Week.
Brad Allan Marder, MD, medical director at Amgen, discussed findings from a trial that investigated the potential benefits of pegloticase in patients with CKD and refractory gout, and how it may influence projected benefits of gout control on the health and economic burden of this cohort.
Researchers used a validated microsimulation model to forecast gout burden in a virtual CKD population. Patients were assigned an eGFR, albuminuria status and serum urate level. Those with gout were assigned complication risks for stroke, diabetes and hypertension in addition to direct and indirect costs, and oral urate-lowering therapies use/efficacy probability. Investigators projected health and economic benefits through 2035.
Findings showed that the prevalence of comorbid gout and CKD was expected to increase from 8.2 million adults in 2023 to 10.5 million by 2035. Related annual costs of gout in patients with CKD were projected to increase from $39.1 billion in 2023 to $50.4 billion in 2035.
Gout is “impactful for both patients’ health and quality of life,” Marder told Healio. “Our study shows there’s something you can do about it [to improve] patients’ health and quality of life and lessen the economic burden of this serious disease.”
Marder and colleagues found that pegloticase use in all patients with CKD with uncontrolled gout could result in 301,000 fewer uncontrolled gout cases, 208,000 quality-adjusted life-years gained and 53,000 complications avoided by 2035, according to the researchers. Compared with baseline, intervention costs would be $23.4 billion less in 2035.
“We projected that by making an intervention in these patients and getting their gout under control, we can not only save many quality years of life and prevent the incidence of many comorbidities,” according to Marder, “but we can also project a savings in direct health care costs and indirect costs of over $50 billion.”
Reference:
Marder BA, et al. FR-PO921. Presented at: American Society of Nephrology Kidney Week; Nov. 2-5, 2023; Philadelphia.
Collapse
Healio Interviews.
Click Here to Manage Email Alerts